Alert: Major Price Advance (12/30/20)-Clovis Oncology Inc (NASDAQ: CLVS).


Clovis Oncology Inc (NASDAQ: CLVS) stock closed at $4.92 on 12/30/20 after a major increase of 10.6%. Moreover, above average trading volume at 144% of normal accompanied the advance. Relative to the market the stock has been extremely weak over the last nine months and has declined -6.2% during the last week.


Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to fall short of the cost of capital, CLVS is expected to be a major Value Eraser.

Clovis Oncology is currently unrated.

Rating Review

The stock is currently unrated.

About John Lafferty 90034 Articles
During his career, John has developed valuation and stock rating methodologies, managed institutional portfolios and mutual funds, and provided equity research to institutional investors on thousands of companies. He has been Director of Research at PTR since its inception in 2004.

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.